Cardiothoracic & vascular anesthesia
Cardiovascular Outcomes of Perioperative Sodium‐Glucose Transporter 2 Inhibition in Cardiac Surgery Patients: An Open‐Label Randomized Pilot Study
Primary result · Postoperative diuresisResult — go to the resultMean difference 549 mL 95% CI 258–839Authors' conclusion
Perioperative SGLT2 inhibition was associated with increased diuresis and lesser fluid accumulation without an increase in vasopressor requirement.
Study context
- Population
- Adults undergoing cardiac surgeryITT analysis
- Participants
- 55 adults
- Comparison
- Perioperative empagliflozin vs standard of care
- Empagliflozinn = 25
- Controln = 30reference
Methodological detailsopen-label, pilot
- Open-label
- Pilot
Primary result
Postoperative diuresis · first 24 postoperative hours
Mean difference
549 mL
95% CI 258–839
P < 0.001
Empagliflozin vs Control
mean difference 549 mL (95% CI 258–839); P < 0.001
As reported in the abstract
Further findings
| Outcome | Mean difference (mL) (95% CI) | P value | |
|---|---|---|---|
| Fluid balance · first 24 postoperative hours | −1217 (−2373- −61) | P = 0.039 | |
| −3000−2000−100001000Difference, mL (linear scale) |
Norepinephrine infusion duration
P = 0.080
IV fluid administered
- Empagliflozin did not increase the amount of IV fluid administered
Postoperative BP and heart rate
- No significant between-group differences
Original publication
Cardiovascular Outcomes of Perioperative Sodium‐Glucose Transporter 2 Inhibition in Cardiac Surgery Patients: An Open‐Label Randomized Pilot Study. Acta Anaesthesiol Scand. Published 22 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →